Prior Authorization. Drug Name (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength

Similar documents
Molina Healthcare of Texas Hepatitis C Drugs (Medicaid)

Circle Yes or No Y N. [If yes, skip to question 13 REAUTHORIZATION REQUESTS]

3. Does the patient meet ALL of the following requirements? Y N

Pharmacy Prior Authorization

Part I. Prior Authorization Criteria and Policy

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

Pharmacy Prior Authorization

Ribavirin (Medicare Prior Authorization)

2. Is the patient responding to medication? Y N

Pharmacy Prior Authorization

Please submit supporting medical documentation, notes and test results.

2. Does the member have a diagnosis of central precocious puberty? Y N

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

2. Is this request for a preferred medication? Y N

3. Has the member received the requested drug for less than 2 years? Y N

3. Have baseline A1c or fasting glucose, thyroid-stimulating hormone (TSH), and electrocardiography (EKG) been checked?

Circle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?

Circle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]

3. Did the patient show evidence of remission by week 8 of Humira Y N therapy?

Address: City: State: ZIP code: Inferferon Product Requested (Include Strength):

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

Pharmacy Prior Authorization

3. Has the member received the requested drug for less than 2 years? Y N

2. Does the patient have a diagnosis of Crohn s disease? Y N

2. Is the patient responding to Remicade therapy? Y N

2. Does the patient have a diagnosis of giant cell arteritis (GCA)? Y N

Circle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.

3. Is the prescribed dose within the Food and Drug Administration (FDA)- approved dosing for giant cell arteritis?

Circle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]

Pharmacy Prior Authorization

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

2. Did the patient receive this medication during a recent hospitalization? Y N

2. Did the member receive this medication during a recent hospitalization? Y N

3. Does the patient have a diagnosis of rheumatoid arthritis (RA) with moderate to high disease activity?

Pharmacy Prior Authorization

3. Does the patient continue to receive nutritional or psychological counseling? Y N

2. Does the patient have chronic urticaria? Y N

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

Circle Yes or No Y N. [If no, then no further questions.]

Prior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

REQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments

[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.

3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?

PEGINTRON (peginterferon alfa-2b) SECTION 1: Pegintron - Hepatitis C Monotherapy

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

Pharmacy Prior Authorization

Pharmacy Prior Authorization

3. Does the member continue to receive nutritional or psychological counseling?

INFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL

Hepatits C Criteria Direct Acting Antiviral Medications

2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N

AmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Circle Yes or No Y N. [If yes, skip to question 29.] 2. Is the request for Sandostatin LAR? Y N. [If no, skip to question 5.] Prior Authorization

Drug Name (specify drug) Quantity Frequency Strength

Prior Authorization. Physician Name: Specialty: NPI Number: Physician Fax: Physician Phone: Physician Address: City, State, Zip:

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Drug Name (specify drug) Quantity Frequency Strength

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

Pharmacy Prior Authorization

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

2. Is the request for Humatrope? Y N [If no, skip to question 6.]

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Length of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

[If yes, no further questions.]

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

2017 United Healthcare Services, Inc.

See Important Reminder at the end of this policy for important regulatory and legal information.

Criteria for Indiana Medicaid Hepatitis C Agents

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Sovaldi Ribavirin. Sovaldi (sofosbuvir) with Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin) Description

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Hepatitis C Medications Prior Authorization Criteria

See Important Reminder at the end of this policy for important regulatory and legal information.

Drug Name (specify drug) Quantity Frequency Strength

Technivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description

Hepatitis C Direct-Acting Antivirals

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Clinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPA.131 Effective Date:

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

PARTNERSHIP HEALTHPLAN OF CALIFORNIA

Zepatier. Zepatier (elbasvir, grazoprevir) and Ribavirin. Description

Clinical Policy: Daclatasvir (Daklinza) Reference Number: CP.PHAR.274 Effective Date: 09/16 Last Review Date: 09/17 Line of Business: Medicaid

Transcription:

06/01/2016 Prior Authorization Aetna Better Health Texas Viekara Pak w or w/o Ribavirin First Fill (Med) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Aetna Better Health Texas (Bexar and Tarrant) at 1-844-275-1084. When conditions are met, we will authorize the coverage of Viekara Pak w or w/o Ribavirin First Fill (Med). Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise. Drug ame (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength Route of Administration Patient Information Patient ame: Patient ID: Patient Group o.: Patient DOB: Patient Phone: Prescribing Physician Expected Length of therapy Other, Please specify Physician ame: Specialty: PI umber: Physician Fax: Physician Phone: Physician Address: City, State, Zip: Diagnosis: ICD Code: Please circle the appropriate answer for each question. 1. Is the requested regimen Viekira Pak with or without ribavirin? [If no, no further questions. Please choose the form that corresponds to the requested regimen.] 2. Has the patient been previously approved for hepatitis C therapy by Texas Medicaid? [If yes, stop review and open Viekira Pak HCV TX Medicaid Refill PA 06-2015.]

3. Is the patient currently on treatment and is transitioning to Texas Medicaid? (ote: Currently on treatment meaning the patient is currently taking medication to treat HCV supplied by a plan other than Texas Medicaid.) [If yes, stop review and open Viekira Pak HCV TX Medicaid Refill PA 06-2015.] 4. Has the patient previously failed to complete treatment with a direct acting HCV agent (e.g., Sovaldi, Harvoni, Olysio, or Viekira Pak)? [If no, skip to question number 7.] 5. Was this failure due to lack of adherence? 6. Was this failure due to a health care plan denial? 7. Is the patient at least 18 years of age? 8. Does the patient have end stage renal disease (i.e., CrCl less than 30 ml/min)? 9. Has the Texas Medicaid/CHIP Vendor Drug Program Patient Education for Hepatitis C Treatment Prescriber Certification form been submitted signed by both the physician and the patient?

10. Has the prescriber confirmed that the patient is mentally competent, able to make appropriate decisions about treatment, and capable of completing therapy? 11. Does the patient have a negative drug test confirmed at least 30 days prior to starting treatment? Drug test to include both legal and illegal drugs which are not verifiable by prescription. 12. Does the patient have a history of substance use disorder? [If no, skip to question number 14.] 13. Has the patient initiated a substance use disorder treatment program at least 6 months prior to the start of treatment? 14. Is the patient consuming alcohol? 15. Is the patient s METAVIR score F0, F1, or F2? [If no, skip to question number 17.] 16. Does the patient have hepatocellular carcinoma or previous liver transplant? [If yes, skip to question number 18.] 17. Is the patient s METAVIR score F3 or F4?

18. If applicable, has the patient or the patient s female partner confirmed that they are not pregnant or attempting conception? (Confirmation via pregnancy test completed within the last 30 days is required for the patient only. If not applicable, answer 19. Are the medications prescribed by, or in conjunction with, a board certified gastroenterologist, hepatologist, or infectious disease specialist? (Collect MDs name.) 20. Has the physician submitted laboratory results for ALL of the following tests that were drawn within the last 30 days? AST (aspartate aminotransferase) \ SCr (serum creatinine) \ CrCl (creatinine clearance) \ Hgb (hemoglobin) \ WBC (white blood cells) \ AC (absolute neutrophil count) \ Plt (platelets) [If no, no further questions. Please submit laboratory results to proceed.] 21. Are all of the tests in compliance with their respective critical values? 22. Has the physician submitted laboratory results for ALL of the following tests? Baseline HCV RA level: Must be drawn within the last 30 days \ METAVIR score: Documentation of tests used to calculate METAVIR score must also be submitted. Either a liver biopsy within the last 5 years or two non-invasive tests (e.g., ActiTest, FIB4, Fibroscan, FibroSURE) from the last two years. [If no, no further questions. Please submit laboratory results to proceed.]

23. Is the virus genotype 1a, 1b, or 4? [If no, skip to question number 25.] 24. Does the patient have decompensated cirrhosis? [o further questions] 25. Is the virus genotype 2 or 3? Comments: I affirm that the information given on this form is true and accurate as of this date. Prescriber (Or Authorized) Signature Prescriber (Or Authorized) Signature Date Date